Affordable Access

deepdyve-link
Publisher Website

A Panel of Three Biomarkers Identified by iTRAQ for the Early Diagnosis of Pancreatic Cancer.

Authors
  • Wu, Xing1
  • Zhang, Zi-Xiang1, 2
  • Chen, Xing-Yu1
  • Xu, Ya-Ling1
  • Yin, Ni3
  • Yang, Jian1, 2
  • Zhu, Dong-Ming1, 2
  • Li, De-Chun1, 2
  • Zhou, Jian1, 2
  • 1 Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215006, China. , (China)
  • 2 Pancreatic Disease Research Centre, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215006, China. , (China)
  • 3 Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215006, China. , (China)
Type
Published Article
Journal
PROTEOMICS - CLINICAL APPLICATIONS
Publisher
Wiley (John Wiley & Sons)
Publication Date
Sep 01, 2019
Volume
13
Issue
5
Identifiers
DOI: 10.1002/prca.201800195
PMID: 31025496
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Due to a lack of early diagnostic markers, pancreatic cancer (PC) remains a lethal disease. Proteomic approaches are now being applied to identify novel PC biomarkers. In this study, iTRAQ and LC-MS/MS are used to perform comparative analyses of serum from PC patients and healthy controls (HC), to identify specific serum biomarkers for PC. Serum levels of candidate proteins are determined using ELISA. Among 869 proteins identified, 55 are potential biomarkers; Vitamin K-dependent protein Z (PROZ) and tumor necrosis factor receptor superfamily member 6b (TNFRSF6B) are selected for further analysis. Serum levels of PROZ and TNFRSF6B are significantly higher in PC patients than in HC or pancreatic benign controls (BC) (p < 0.01). The AUCs range from 0.816 to 0.971 for PROZ, TNFRSF6B, and carbohydrate antigen 19-9, either individually or in combination, in PC versus HC+BC, and from 0.711 to 0.932 in PC Stage I versus HC+BC. It is demonstrated that PROZ and TNFRSF6B are novel serum biomarkers for detecting early stage PC, and for distinguishing PC from pancreatic benign tumor and healthy individuals. Additional large cohort studies are needed to develop PROZ and TNFRSF6B as clinical PC biomarkers. © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Report this publication

Statistics

Seen <100 times